Öz
Amaç
Bu çalışmada, kadınlarda benign ve malign adneksiyal kitleleri ayırt etmede sistemik immün-enflamatuvar indeksin (SII) öngörücü rolünün araştırılması amaçlanmıştır.
Yöntemler
Adneksiyal kitle nedeniyle opere edilen, final patoloji sonuçlarına göre benign tümör veya epitelyal over kanseri tanısı alan 268 kadın çalışmaya dahil edildi. Hastaların tam kan sayımı ve kanser antijeni 125 (CA125) düzeyleri gibi verileri retrospektif olarak toplandı ve değerlendirildi. Bilinen kanser tanısı olan, non-epitelyal over kanseri olan, enflamatuvar, hematolojik veya otoimmün hastalığı olan hastalar çalışmadan çıkarıldı.
Bulgular
Çalışmaya, 177 benign ve 91 malign epitelyal over tümörü olan kadın dahil edildi. SII ve CA125, iki grup arasında anlamlı farklılık gösterdi ve her iki belirteç de malign grupta anlamlı şekilde daha yüksek bulundu (p<0,001). SII ve CA125’in maligniteyi öngörmedeki eğri altında kalan alanları sırasıyla 0,779 ve 0,814 idi. Univaryant ve multivaryant lojistik regresyon analizleri, yüksek preoperatif CA125 düzeyi (>160) ve yüksek SII (>5,63) ile malign tümörlere sahip olma riskinin arttığını gösterdi (p<0,001).
Sonuç
Bulgularımız, SII’nın CA125 ile birlikte, benign ve malign adneksiyal kitleleri ayırt etmek için umut vaat eden öngörücü bir belirteç olduğunu göstermektedir. CA125 ile birlikte SII’nın entegrasyonu, tümör mikro çevresindeki enflamatuvar ve immün yanıt hakkında değerli bilgiler sağlayarak tanısal doğruluğu artırır.
Anahtar Kelimeler: Adneksiyal kitle, over kanseri, sistemik immün-enflamutuvar indeks, öngörücü belirteç
Kaynakça
Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31:681-90.
Prat J. Ovarian tumors: a review. Histopathology. 2018;72:3-21.
Gupta JK. Diagnosis and management of adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2009;23:697-709.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016;128:210-26.
Zanetta G, Mariani E, Lissoni A, Ceruti P, Trio D, Strobelt N, et al. A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy. BJOG. 2003;110:578-83.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-45.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-37.
Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). 2019;11:564.
Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18:59.
Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR 2nd. Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review. Cancers (Basel). 2022;14:2885.
Kose C, Korpe B, Korkmaz V, Ustun YE. The role of systemic immune inflammation index in predicting treatment success in tuboovarian abscesses. Arch Gynecol Obstet. 2023;308:1313-9.
Köse C, Körpe B, Kurdoğlu Z, Korkmaz H, Ustun YE, Korkmaz V. Predictive utility of systemic immune inflammation index (SII) in identifying endometrial carcinoma in premalignant endometrial lesions. Van Med J. 2023;30:418-25.
Wang J, Yin S, Chen K. Predictive value of the systemic immune-inflammation index for the efficacy of neoadjuvant chemotherapy and prognosis in patients with stage III ovarian cancer-a retrospective cohort study. Gland Surg. 2022;11:1639-46.
Mao H, Yang F. Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: a meta-analysis. Front Oncol. 2023;13:1193962.
Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33:e22964.
Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1-5.
Bullock B, Larkin L, Turker L, Stampler K. Management of the adnexal mass: considerations for the family medicine physician Front Med (Lausanne). 2022;9:913549.
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. Cancers (Basel). 2020;12:3730.
Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20:464.
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265-73.
Bizzarri N, D'Indinosante M, Marchetti C, Tudisco R, Turchiano F, Scambia G, et al. The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer. Int J Clin Oncol. 2023;28:314-20.
Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet. 2018;297:849-57.
Zhang CL, Jiang XC, Li Y, Pan X, Gao MQ, Chen Y, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR. J Ovarian Res. 2023;16:36.
Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflamm Res. 2017;66:467-75.
Feng J, Wang Q. Correlation of systemic immune-inflammatory response index with clinical data in patients with malignant ovarian tumor. Am J Transl Res. 2023;15:3309-17.
Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18:443.
